Author | Josep M. Llovet, MD, PhD | OncLive

Author | Josep M. Llovet, MD, PhD

Articles

Dr. Llovet on REACH Trials With Ramucirumab in HCC

July 17, 2019

Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.

Dr. Llovet on Precision Medicine in HCC

October 19, 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

x